AFP Level Chart for Liver Cancer: Prognosis and Severity

Alpha-fetoprotein (AFP) levels offer a rough but useful gauge of liver cancer severity, with higher readings generally tied to larger tumors, more aggressive biology, and shorter survival. In one large study, patients with AFP at or above 1,000 ng/mL faced more than four times the mortality risk of those below 10 ng/mL. But AFP is far from a clean ruler: roughly a third of liver cancers never push AFP above normal, and a number of non-cancer conditions can send it soaring. Understanding what different AFP ranges actually signal, and where the test falls short, helps you make sense of lab results that can otherwise feel opaque or alarming.

What AFP Is and What “Normal” Means

AFP is a protein produced in large quantities by a developing fetus, where blood concentrations can reach millions of micrograms per liter. After birth, the gene that drives AFP production gradually winds down, and by age two, serum levels settle into the adult range of roughly 0.5 to 15 micrograms per liter (equivalent to about 0.5–15 ng/mL).¹ When liver cells become cancerous, many of them switch that fetal gene back on and start secreting AFP into the bloodstream. This is why AFP is called an “oncofetal” marker: it bridges fetal development and cancer biology.² Most labs flag anything above 10–20 ng/mL as worth investigating, though context matters enormously.

Diagnostic Thresholds and Their Tradeoffs

There is no single AFP cutoff that neatly separates “cancer” from “no cancer.” A systematic review and meta-analysis pooling dozens of studies showed just how sharply the tradeoff between sensitivity and specificity shifts depending on where you draw the line. At a threshold of 400 ng/mL, specificity was extremely high (about 99%), meaning almost no false positives, but sensitivity was only around 32%, meaning roughly two out of three cancers were missed. Dropping the threshold to 200 ng/mL raised sensitivity to about 49% while keeping specificity near 98%. At thresholds between 20 and 100 ng/mL, sensitivity climbed to about 61%, but specificity fell to around 86%.³

In practical terms, a very high AFP (above 400 ng/mL) in someone with chronic liver disease and a liver mass is almost certainly cancer. A mildly elevated AFP in the 20–100 range is less definitive and needs to be paired with imaging. And a normal AFP does not rule cancer out. This variability across cutoffs is one reason AFP’s utility has been debated for decades; its accuracy shifts depending on the threshold chosen, the patient population studied, and even the lab assay used.⁴

What Higher AFP Tells You About Tumor Behavior

AFP is not just a screening number. It correlates with several features that make liver cancer more dangerous. Chief among these is vascular invasion, where tumor cells grow into blood vessels. This is a major predictor of recurrence and death. A study of hepatitis B-related liver cancer found a significant association between high AFP expression and the presence of vascular invasion.⁵ In patients awaiting liver transplant, AFP above 100 ng/mL carried a fivefold higher odds of microvascular invasion compared to lower levels.⁶ And in tumors larger than 5 cm, an AFP level of at least 1,000 ng/mL predicted hidden vascular invasion alongside high tumor grade and multiple nodules.⁷

The connection between AFP and tumor grade matters too. A large population-level analysis identified AFP at diagnosis as an independent predictor of pathological grade, disease progression, and survival, whether or not the patient had surgery.⁸ In short, higher AFP at diagnosis is a marker of biologically aggressive cancer, not just bigger cancer.

AFP and Survival

When it comes to predicting who lives longer after a liver cancer diagnosis, AFP has real but imperfect value. A study of patients with hepatitis C-related liver cancer divided AFP into tiers: below 10, 10 to under 100, 100 to under 1,000, and 1,000 or above. Compared to the lowest tier, the hazard ratios for death were roughly 1.5, 2.2, and 4.4, respectively, each step up representing a meaningfully worse prognosis.⁹ That gradient is steep: a patient in the highest AFP bracket faced more than quadruple the mortality risk of someone in the lowest.

After surgery, preoperative AFP level continues to predict outcomes. One study comparing patients in three groups (AFP ≤ 20, 20–400, and > 400 ng/mL) found that the low-AFP group had lower two-year recurrence rates and higher 18- and 24-month survival rates than the other groups.¹⁰ So even after the tumor is removed, the AFP value recorded before surgery carries forward as a signal about what comes next.

When AFP Is Normal Despite Cancer

This is the wrinkle that surprises many patients: a substantial fraction of hepatocellular carcinomas produce little or no AFP. Estimates vary, but roughly 30–40% of liver cancers present with AFP below the standard cutoff. A study focused specifically on patients who had normal AFP found that their outcomes were driven by factors like vascular invasion, tumor size, treatment approach, and liver function rather than AFP itself. In that group, AFP was not an independent predictor of overall survival in multivariate analysis.¹¹

This does not mean normal-AFP cancers are necessarily less aggressive. Some of them are caught at an early stage (which is favorable), but others include poorly differentiated tumors that simply lack the molecular machinery to secrete AFP. The takeaway is that AFP works as a prognostic tool mainly when it is elevated. A normal AFP reading in a confirmed cancer should not be misread as reassuring on its own.

Very Early Tumors With Very High AFP

On the other end of the spectrum, some patients present with very small tumors yet paradoxically sky-high AFP. A study looking specifically at very early hepatocellular carcinoma in patients who underwent surgical resection found that very high AFP was not independently associated with recurrence in that setting. Factors like liver cirrhosis and hepatic reserve drove recurrence instead.¹² This is a genuinely counterintuitive finding: even a markedly elevated AFP does not automatically doom a patient when the tumor itself is tiny and caught early. It reinforces that AFP has to be interpreted alongside tumor stage, not in isolation.

Non-Cancer Causes of Elevated AFP

AFP can rise substantially without cancer being present, which is a major source of false-positive anxiety. High levels (above 100 ng/mL) have been documented in acute liver failure, flares of chronic hepatitis, pregnancy, massive metastatic involvement from non-liver cancers, and germ-cell tumors.¹³ Chronic hepatitis and cirrhosis commonly produce mildly to moderately elevated AFP because inflamed or regenerating liver cells can reactivate the gene.¹⁴ For patients already being monitored for liver cancer risk, these benign elevations can be confusing. A single elevated AFP value in the absence of a visible mass is not enough to diagnose cancer; the trend over time and imaging findings have to be considered together.

Tracking AFP After Surgery and the Half-Life Concept

Once a liver tumor is removed, how quickly AFP falls gives clinicians an early signal about whether the surgery got everything. AFP has a natural half-life, the time it takes for levels to drop by half. In patients whose tumors were completely removed and who stayed free of recurrence, the half-life averaged about 4 days. In patients with incomplete removal or later recurrence, the half-life stretched to roughly 25 days, a strikingly significant difference.¹⁵

Studies in adults echo this pattern. When the AFP half-life after liver resection exceeded 7 days, early recurrence within two years was found in about 59% of patients, compared to roughly 29% in those with a normal half-life. Prolonged half-life independently predicted shorter recurrence-free and overall survival.¹⁶ A separate analysis confirmed that a long AFP half-life (7 days or more) was an independent risk factor for poor recurrence-free and overall survival after hepatectomy.¹⁷ Monitoring the speed of AFP decline, not just whether it normalizes eventually, can flag trouble well before imaging picks up a recurrence.

AFP in Liver Transplant Decisions

Liver transplant is a potential cure for hepatocellular carcinoma, but not every patient qualifies, and AFP plays a growing role in eligibility. Traditional criteria focused on tumor number and size. Adding AFP into a scoring model improves prediction of post-transplant recurrence. One model showed that even among patients whose tumors exceeded the traditional size-and-number criteria, those with an AFP-based score of 2 or lower (corresponding to AFP below 100 ng/mL) had a five-year recurrence risk of about 14%, compared with roughly 48% in those who scored higher.¹⁸

A validation study in viral hepatitis patients confirmed these findings: five-year recurrence rates split sharply by AFP score, at roughly 13% versus 50%.¹⁹ French transplant guidelines have formally adopted an AFP-based score for eligibility, and the concept is gaining traction internationally. In patients whose tumors initially fall outside criteria, “downstaging” (shrinking the tumor with treatment before transplant) is sometimes attempted. An AFP that fails to respond adequately during downstaging, specifically remaining at or above 20 ng/mL with less than 50% decline from the peak, independently predicted downstaging failure.²⁰ AFP dynamics during this period guide whether to proceed with transplant or change course.

An AFP model also independently correlated with other high-risk features like vascular invasion, poor differentiation, and capsule invasion after curative resection, extending its predictive utility beyond transplant selection alone.²¹

AFP-L3, a More Cancer-Specific Version of AFP

Total AFP lumps together several glycoforms, which are structurally slightly different versions of the same protein. The form most tightly linked to cancer is called AFP-L3 (the fraction that binds to a particular lectin). While cirrhosis and chronic hepatitis tend to raise the non-L3 forms, AFP-L3 is more specific to malignant liver cells.¹⁴ The clinical question is how useful the L3 fraction is in practice.

In patients whose total AFP falls in the diagnostically ambiguous zone of 10–200 ng/mL, an AFP-L3 percentage above 35% was 100% specific for cancer, meaning no false positives. That allowed confident diagnosis of an additional 10% of cancers that would have been missed by total AFP alone at the 200 ng/mL cutoff. The tradeoff was low sensitivity (about 33%) at that strict threshold.²² A meta-analysis of AFP-L3 for early-stage cancer found pooled sensitivity of about 34% but specificity over 92%, reinforcing the pattern: AFP-L3 is good at ruling cancer in but not great at ruling it out.²³

AFP-L3 also carries prognostic weight. A systematic review and meta-analysis found that high pretreatment AFP-L3 levels were associated with worse overall and disease-free survival, even in patients whose total AFP was low.²⁴ If your total AFP is unremarkable but your AFP-L3 percentage is climbing, that combination may warrant closer attention.

Combining AFP With Other Biomarkers

Because AFP alone misses a meaningful fraction of cancers, clinicians increasingly pair it with PIVKA-II (also called DCP), a protein produced when liver cancer cells can’t properly process a clotting factor. An expert consensus from the Asia-Pacific region concluded that PIVKA-II is valuable for detecting cancer in AFP-negative patients and improves early detection when used alongside AFP.²⁵ In one analysis, combining AFP with PIVKA-II boosted the area under the curve (a summary measure of diagnostic accuracy) from about 0.80 for AFP alone to 0.85 for the pair, with sensitivity rising from roughly 58% to 72%.²⁶ Adding a third marker (GP73) pushed accuracy even higher in some hepatitis B populations, with the triple combination reaching an area under the curve above 0.90.²⁷

A particularly promising composite tool is the GALAD score, which combines gender, age, AFP-L3, AFP, and DCP (PIVKA-II) into a single number. In one study, GALAD achieved an area under the curve of 0.94 for detecting liver cancer, outperforming each individual marker. For early-stage disease (BCLC stage 0 or A), GALAD reached 100% sensitivity.²⁸ A German study similarly found GALAD outperformed any single marker or two-marker combination for early-stage cancer detection, with sensitivity above 85% and specificity above 93%.²⁹ Not all settings match these optimistic numbers; a separate study found the GALAD area under the curve at a more modest 0.80, though it still significantly differentiated cancer from non-cancer.³⁰ GALAD is not yet universally adopted in clinical guidelines, but it represents the direction surveillance is heading.

AFP Sensitivity Varies by Ethnicity

One underappreciated factor is that AFP performs differently across ethnic groups. A study comparing hepatitis C patients found that AFP sensitivity for diagnosing liver cancer was markedly lower in African Americans than in other groups (about 57% versus 82% at a cutoff of 10 ng/mL). The area under the ROC curve was only 0.56 for African Americans, barely better than a coin flip, versus 0.81 for non-African Americans.³¹

A separate study comparing Egyptian and Japanese patients found the opposite pattern in a different direction: Egyptian patients had dramatically higher AFP sensitivity (99% versus 67% at a 10 ng/mL cutoff), and the difference persisted regardless of age, sex, cirrhosis status, or tumor characteristics.³² The reasons for these disparities are not fully understood, though differences in underlying viral hepatitis type, tumor biology, and genetic factors in AFP expression likely all play a part. Clinically, it means a fixed AFP cutoff applied identically across all populations will over-diagnose in some groups and under-diagnose in others.

AFP Response During Immunotherapy

The newest wrinkle in AFP monitoring involves patients receiving modern combination immunotherapy for advanced liver cancer. When treatment with checkpoint inhibitors combined with anti-angiogenic drugs triggers a meaningful response, AFP levels tend to drop quickly. A study of patients on bevacizumab plus immunotherapy found that the cohort whose AFP fell sharply had the best clinical outcomes. Various thresholds for defining an AFP “response” have been proposed (a drop of 10–20% depending on the regimen), but the broad pattern holds: a rapid AFP decline during immunotherapy predicts better progression-free and overall survival.³³

A separate analysis confirmed that AFP response (defined as a decline of more than 15% within the first three months of checkpoint inhibitor therapy) was an independent predictor of disease control, progression-free survival, and overall survival. Patients with an AFP response had roughly half the hazard of disease progression and about a third the hazard of death compared to non-responders.³⁴ This is important because imaging-based tumor response can be ambiguous during immunotherapy, sometimes showing initial swelling before shrinkage. AFP trends offer a complementary, real-time readout that can guide early clinical decisions about whether a regimen is working.

Whether AFP Screening Is Worth the Cost

For patients with chronic liver disease, the practical question is whether regular AFP testing, usually done every six months alongside ultrasound, delivers enough benefit to justify the expense and the occasional false-positive scare. A cost-effectiveness analysis found that combining ultrasound with AFP was the dominant strategy over ultrasound alone or no surveillance. The combination was cost-effective in roughly 80% of model simulations. The analysis also identified a minimum cancer incidence threshold of about 0.4% per year for AFP-plus-ultrasound screening to be worthwhile compared to no screening at all.³⁵ Since patients with cirrhosis generally have an annual cancer incidence well above that threshold, the economics support keeping AFP in the surveillance toolkit for high-risk populations, despite its imperfect sensitivity.

AFP and Psychological Burden

What rarely gets discussed is the emotional weight of AFP monitoring. A prospective study of patients with advanced liver cancer found that over half scored above the threshold for anxiety or depression, and AFP level was significantly correlated with that psychological distress. Higher AFP may not just signal worse disease; it may compound the emotional toll of a cancer diagnosis, particularly when patients track their numbers closely. Clinicians are increasingly aware that AFP results need to be communicated in context, with an explanation of what the number does and does not mean, rather than delivered as a raw figure that a patient then researches alone. The temptation to interpret a rising AFP as a death sentence, or a normal AFP as an all-clear, leads to real harm in both directions.